Live pharmacies

Galarraga Aiestaran, Ana

Elhuyar Zientzia

The production of human proteins for therapeutic use is not easy. In the laboratory, they can be produced in cultures of microorganisms or yeasts or in cell cultures. But it is a difficult and expensive process. Is it easier and economical to create in genetically modified animals? Or in transgenic plants? Some researchers believe that yes and are advancing on that path.
Live pharmacies
01/07/2007 | Galarraga Aiestaran, Ana | Elhuyar Zientzia Komunikazioa
(Photo: US Health Institute; Archive)

A year ago, the European Medicines Agency (EMEA) authorized the first time worldwide commercialization of a drug produced by a transgenic animal. Specifically, it authorized the use of the ATryn protein produced in milk by genetically modified goat. This protein, produced by GTC Biotherapeutics, is a human antitronbin, anticoagulant. Prevents the formation of coáginas in patients with deficiency of this protein.

Months earlier, the agency did not authorize this antitronbin because it was tested in clinical trials in very few patients. But the lack of antitrobine is a rare disease, only one in 3,000 and 5,000 people suffer, so it is not easy to get many volunteer patients. However, it was subsequently decided that the evidence submitted by GTC was sufficient. Among the volunteers were also pregnant women, and experts showed that antitronbine is totally safe and has the same efficacy in both non-pregnant and pregnant women.

In addition to the GTC company, other companies generating therapeutic substances in transgenic animals took the news with hope. For a long time they expected to open the market doors and soon saw the conclusion of the step taken by SAME: GTC's market value grew by more than 20% and that of its close competition, the Pharming company, grew by almost 10%.

In addition, two weeks after its authorization in ATry, SAME authorized the commercialization of an anti-inflammatory drug produced by Pharming through transgenic rabbits. It was thought that behind this others were going to go.

It is not so. And it is that they have to guarantee that the topics created in transgenic animals are safe and for this they must overcome a lot of tests. In particular, they should consider four points: allergic responses, immune system response, autoimmune response, and infections, including those caused by prions. To ensure and demonstrate that they are safe from all parties, they must use a very advanced technique and present numerous tests. And for this it takes a lot of time and money.

Some diseases occur because the patient has no topic in the blood. Sometimes, the only treatment is the administration and injection of this substance into the blood of a donor.
From file

Very special milks

Ten years ago, however, the drawbacks were not known and many researchers expected much in this field. In 1996 the Roslin Institute presented Dolly, the first cloned animal of an adult cell. A year later, in the same institute, two other cloned sheep, Molly and Polly, were born. They did not resemble Dolly much, but were characterized by having a human gene in their genome.

This gene encodes the protein called factor IX. It is a blood clotting protein that is used to treat hemophilia, which is what they lack in the blood. But the only source to obtain factor IX is the blood plasma of human beings and for it they created Molly and Polly to create a flock of sheep that would contribute factor IX in milk. This would represent an important market for this protein.

Therefore, to produce biological molecules such as proteins, antibodies, genetic engineering looked like a great opportunity. Until then, cell cultures of microorganisms, yeasts or animals or people were used, and that is the main route. However, it is a difficult and expensive method, in which the molecules produced in cultures require complex changes to be used in therapy, obtaining also small amounts. For this reason, they considered that the transformation of animals into drug producers could cover the product.

Therefore, they have tried to do so. Molly and Polly did not meet their goal, but researchers have continued to work with cows, sheep and goats. In fact, these animals are used to produce milk, and if, thanks to genetic engineering, these and their descendants manage to form human molecules in milk, we only have to isolate proteins from milk.

This goat forms in its milk an anticoagulant protein in human blood.
GTC Biotherapeutics

On this path, the work carried out by the company GTC with goat has paid off and it is estimated that obtaining antitronbine by transgenic goat is between 30 and 100 times cheaper than production in cell cultures.

Cows produce more milk than goats, so they were selected by Advanced Cell Technology. In the milk of transgenic cows it was intended to obtain the protein seroalbumin of the human blood. Seroalbumin is used to increase blood volume, for example in patients with traumatic injuries. It was considered that cow's milk could be an unbeatable source, since a single cow can provide more than 8,000 liters of milk a year, which could mean between 40 and 80 kilos of protein.

However, this field has not been the expected development. Many projects have been left on the road and, although at present the market of these molecules for therapy moves 24.500 million euros, the products produced from genetically modified animals continue to occupy a very small part.

Eggs and plants

However, researchers do not give up and now they also want to produce human proteins of medical utility in eggs. The method is similar to that used in ruminants. Like ruminants in milk, genetically modified chickens produce therapeutic protein in eggs.

The researchers want to produce human proteins of medical utility in eggs of transgenic hens.
From file

The cultivation of transgenic hens has certain advantages over cattle. They are cheap, productive (each chicken can lay 300 eggs a year) and the intergenerational distance is small. This facilitates the adaptation of production to demand.

The Roslin Institute, in collaboration with Viragen and Oxford Biomedica, has managed to produce two therapeutic proteins in the clear of transgenic chicken eggs. One of them is the Mini-R24 antibody, allegedly useful against malignant melanoma, and the other human interferon b-1, used to treat multiple sclerosis and other diseases. The research, published this year in the scientific journal PNAS, aims to continue investigating to improve the results.

However, in addition to chickens, ruminants have other competitors: the plants. Researchers have been looking for years so that plants have characteristics that they want to genetically transform, including the ability to produce human proteins and vaccines.

Transgenic plants are easier to grow than animals and also have a lower risk of virus or prion infection. On the contrary, they cause more allergies and, above all, they have a high risk of spreading to the environment. In fact, for many people this is one of the biggest reasons to be against GM crops. Therefore, manufacturers are required to take drastic measures to avoid this risk.

For example, researchers at the US Purdue University grow transgenic plants in a mine located in Indiana. In this way, it is guaranteed that the external plants will not be affected. They research with maize, tobacco, alfalfa and soybeans, among others, to create antibodies, insulin and vaccines.

To ensure their environmental safety, researchers at Purdue University in the United States grow transgenic plants in a mine located in Indiana.
Purdue University

There are numerous studies of transgenic plants capable of producing this type of molecules, and recently the U.S. Department of Agriculture. has received the authorization to grow rice that produces proteins found in the female milk. Transgenic rice contains lysozima, laktoferrin and human seroalbumin. Lysozyme and laktoferrin have antibacterial, viral and fungal properties, and with rice, researchers want to make a drink to treat diarrhea and anemia.

Despite the problems, genetically modified animals and plants are becoming a source of therapeutic molecules. However, they are still in their beginnings, while the effectiveness of the systems of generation of these molecules in cell cultures is increasing. Time will tell what is the best way, for now researchers do not want to close the door.

How to convert goat into a laboratory
ATryn is a human goat milk protein. To do this it is necessary to genetically transform the goats, introducing in the genetic code of the goats the gene that encodes this human protein. In addition, the gene should only be expressed in breast cells. Thus, this protein is only in milk. Finally, the protein must be isolated and purified. The company GTC Biotherapeutic has worked and patented a method for this.
First, they add to the gene that encodes the therapeutic protein the genetic information necessary to express themselves in the breast cells. With this they create a transgene that contains both information. Then they take a fertilized ovum from a goat and inject the transgene.
(Photo: From archive)
The osculum containing the transgene is placed in the uterus of another goat and check if the cabrite that is born has transgenic in the genetic code, since it is not inserted correctly in all of them. If it has transgen, it produces human protein in milk.
However, the production of this first generation varies greatly from one goat to another. Therefore, they choose the most suitable ones and, as the capacity of production of proteins is hereditary, they cross them. The production of transgenic goats of the next generation is homogeneous and, in addition, produces a lot of proteins. Once the protein is purified, it is marketed in white powder.
Milk with spider threads
The use of transgenic ruminants, such as the Biosteel Thread, allows obtaining not only human proteins for therapy, but also other topics of interest.
Biosteel Nexia Biotechnologies is a spider thread created by transgenic goats. The spider thread has numerous applications, biodegradable and extremely hard, elastic and light. With a diameter ten times smaller than a head, it can stop to a bee that goes to 3.2 kilometers per hour.
A: A: Spider thread produced in goat milk, expanded on 500 occasions. B: B: Broken thread to show the structure.
(Photo: A. A. Lazaris/Science)
But spiders are very aggressive and cannot grow like cetares. In addition, it does not serve the entire network of spiders, it only serves the type of thread used to form the structure of the network. It has been tried to produce in cell cultures, but strings are obtained too short.
With genetic engineering, Nexia Biotechnologies has managed to create the type of yarn you want in goat milk and markets it under the name of Biosteel. It is indicated for the manufacture of medical material (bandages, patches, prosthesis...) and has applications in other fields as sports equipment.
Galarraga de Aiestaran, Ana
Services Services Services
233 233 233
2007 2007 2007 2007 2007
Others
036 036 036
Biotechnology; Medicine; Pharmacy; Livestock; Genetics; Ethics
Article Article Article
Description Description Description Description
Babesleak
Eusko Jaurlaritzako Industria, Merkataritza eta Turismo Saila